Clinically significant mutations in HIV-infected patients with lung adenocarcinoma
Menée aux Etats-Unis à partir d'échantillons tumoraux prélevés sur 55 patients atteints d'un adénocarcinome pulmonaire et infectés par le VIH et sur 136 patients non infectés par le VIH, cette étude de cohorte analyse la présence de mutations des gènes EGFR et KRAS en fonction de la séropositivité
Background: Lung cancer is a major cause of death in HIV-infected (HIV+) persons. In this study, we compared the prevalence of tumour EGFR and KRAS mutations in a cohort of lung adenocarcinoma patients by HIV status. Methods: We collected data from 55 HIV+ patients with lung adenocarcinoma matched to 136 uninfected comparators. We compared the prevalence of EGFR and KRAS mutations by HIV status. We then compared survival by HIV status and by cancer mutation status among HIV+ subjects. Results: Presence of KRAS and EGFR genetic alterations did not vary by HIV status (all P>0.1). There was no difference in overall survival by HIV status or by mutation status among HIV+ subjects. Conclusions: We found no major differences in the prevalence of EGFR or KRAS lung adenocarcinoma mutations by HIV status, suggesting that mutational testing should be conducted similarly regardless of the HIV status.